NCT00291655View on ClinicalTrials.gov

Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).

PHASE3CompletedINTERVENTIONAL

Enrollment

130

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions

Epilepsy

Interventions

DRUG

Levetiracetam

500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study

Trial Locations (35)

Unknown

Bruges

Edegem

Ghent

Haine-Saint-Paul

Jette

Kortrijk

Leuven

Ostend

Sofia

Varna

Hus (helsinki)

Kuopio

Tampere

Blaye

Bordeaux

Brest

Carcassonne

Cherbourg

Lille

Lyon

Nancy

Rennes

Saint-Brieuc

Saint-Quentin

Toulouse

Valenciennes

Częstochowa

Krakow

Olsztyn

Poznan

Warsaw

Biel

Lausanne

Sankt Gallen

Zurich

Sponsors

Lead Sponsor

All Listed Sponsors

lead

UCB Pharma

INDUSTRY

NCT00291655 - Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903). | Biotech Hunter | Biotech Hunter